Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
By The Akkermansia Company
$44.85
Capsule
30
August 31, 2026
The Akkermansia Company Akkermansia Essential is a dietary supplement. It is not FDA-approved, has not been reviewed for safety or effectiveness before sale, and is not a treatment for any disease. It is not equivalent to and does not replace prescription semaglutide or tirzepatide. No claim on this page should be read as a promise of weight loss.
This is the product with the closest link to the actual science. The Akkermansia Company commercialises the pasteurized Akkermansia muciniphila strain MucT (ATCC BAA-835) that came out of the UCLouvain research programme — the same form used in the human proof-of-concept trial that the entire Akkermansia supplement category cites.
Akkermansia Essential delivers 30 billion TFU of pasteurized A. muciniphila in a 150 mg capsule, taken once daily. The company describes it as a next-generation postbiotic rather than a probiotic, which is technically the correct term — pasteurized bacteria are not alive.
That distinction is the reason to care. Research has reported the pasteurized form as more potent than the live form for glucose tolerance, and EFSA has approved pasteurized A. muciniphila as a safe novel food. Most of the category sells live Akkermansia while citing pasteurized research.
Serving size: 1 capsule (150 mg) · 30 servings per container
| Ingredient | Amount | % DV |
|---|---|---|
| Pasteurized Akkermansia muciniphila MucT (ATCC BAA-835)Pasteurized (heat-inactivated), making this a postbiotic rather than a live probiotic. This is the strain and form used in the published human trial. | 30 billion TFU per 150 mg capsule | Daily Value not established |
Check the current label. The company's separate Gut Support product additionally contains chamomile extract and B vitamins.
Marketed to support weight management, intestinal barrier function, glucose metabolism and healthy insulin levels.
Positioned as a next-generation postbiotic that reinforces intestinal barrier function and supports glucose metabolism, based on the company's own published research programme.
The Depommier et al. proof-of-concept trial in overweight and obese volunteers used pasteurized A. muciniphila. This product uses that same pasteurized MucT strain, which is a materially stronger evidence link than live-Akkermansia products can claim.
Research comparing the forms reported the pasteurized form as more potent than the live form in improving glucose tolerance, and ISAPP has described pasteurization as maintaining and even increasing Akkermansia's effects.
EFSA approved pasteurized Akkermansia muciniphila as a safe novel food — a level of regulatory assessment almost nothing else in this category has.
Reporting on later clinical work describes participants receiving pasteurized A. muciniphila MucT regaining significantly less weight — on average about three kilograms less.
The headline trial was explicitly a proof-of-concept exploratory study, and its body-weight result did not reach statistical significance (−2.27 ± 0.92 kg versus placebo, P = 0.091). Improvements in insulin sensitivity and some metabolic markers were the more notable findings, not weight loss. A published critical perspective stresses the overall evidence base is still developing. Nothing here establishes that this product produces weight loss.
One capsule daily per the label.
Consult a physician before use if pregnant, nursing, or managing a medical condition. Because the bacteria are pasteurized rather than live, the usual live-probiotic caution for immunocompromised people is less applicable — but check with your clinician regardless.
Not publicly listed in the material we reviewed. Check the current label.
Listed as a 31% saving with free shipping
30 daily capsules
Bundle pricing
30 daily capsules, 150 mg per capsule
Subscription pricing at $44.85 per month with free shipping, listed as a 31% saving against the one-time price. Confirm cancellation terms at checkout.
Not publicly confirmed in the material we reviewed.
Direct and through retailers including Target. Pasteurized product does not require the cold-chain handling live probiotics do, which is a genuine practical advantage.
Pricing reflects what The Akkermansia Company and named third-party retailers published as of August 31, 2026. Supplement pricing changes frequently — confirm at checkout.
People who want the specific form and strain that the human research actually used, and who would rather pay more for that alignment than buy a cheaper live product whose evidence link is weaker.
Cost is the deciding factor — Codeage delivers a disclosed live dose for roughly a third of the price. Also skip it if you want a multi-strain or synbiotic formulation, since this is a single pasteurized ingredient.
For the outcomes most studied, the evidence currently favours pasteurized. The human proof-of-concept trial used the pasteurized form, research comparing the two reported pasteurized as more potent for glucose tolerance, and ISAPP has described pasteurization as maintaining and even increasing Akkermansia's effects. EFSA has approved pasteurized A. muciniphila as a safe novel food.
$44.85 per month on subscription with free shipping, $65.00 for a one-time one-month supply, or $134.55 for three months. Retailers including Target have listed it around $58.50 for 30 capsules.
Pasteurized Akkermansia muciniphila MucT (ATCC BAA-835) at 30 billion TFU per 150 mg capsule — the same strain and form used in the published human proof-of-concept trial.
Not conclusively. Pasteurized A. muciniphila supplementation slightly decreased body weight versus placebo (−2.27 ± 0.92 kg) but the result did not reach statistical significance (P = 0.091). The more notable findings were in insulin sensitivity and metabolic markers. It was an exploratory proof-of-concept study.
No. Because the bacteria are pasteurized rather than live, there is no viability to protect and no cold chain to manage — a real practical advantage over live probiotic competitors.
It depends what you are buying. If you want the exact form the research used, this is the only product that gives you that, and the premium is defensible. If you want Akkermansia at the lowest cost with a disclosed dose, Codeage delivers live AH39 at roughly $13.33 a month.
Every ingredient, dose, price and policy on this page traces to one of these, checked August 31, 2026.
Speak to a qualified healthcare provider or pharmacist before starting this or any supplement — particularly if you take prescription medication, are pregnant or breastfeeding, are immunocompromised, have a chronic condition, or are already taking a GLP-1. A pharmacist can screen your full medication list for interactions in a few minutes, and that is worth doing before you spend anything.
Explore more expert guides and reviews to help you on your weight loss journey
Ranked on published ingredient amounts, evidence quality and real cost. Paid placement disclosed.
Six products side by side on ingredients, amounts, form and price.
The butyrate and Akkermansia pathway explained, and where the evidence stops.
Fibre and protein have the evidence. Most branded appetite products do not.
Metabolic health is measurable, which makes this a category you can actually test.
Assessed at strain level, where probiotic evidence actually lives.
These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not FDA-approved, are not reviewed for safety or effectiveness before sale, and are not intended to diagnose, treat, cure, or prevent any disease. Nothing on this page is a substitute for prescription medication, and no supplement described here has been shown to produce weight loss comparable to a prescription GLP-1 medication. Individual results vary. Supplements can interact with prescription medications — talk to a qualified healthcare provider or pharmacist before starting anything, particularly if you are pregnant, breastfeeding, immunocompromised, taking other medication, or already on a GLP-1.
This page contains affiliate links, and we may earn compensation if you use them. Last reviewed: August 30, 2026